Exelixis rises after cancer therapy succeeds in late-stage study

Exelixis

23/06/2025 12:00

** Shares of drugmaker Exelixis EXEL.O rise 23.8% to $49.97 premarket

** EXEL on Sunday said its experimental oral therapy zanzalintinib, combined with Roche's ROG.S Tecentriq, improved survival in patients with a type of colorectal cancer in a late-stage study

** Colorectal cancer develops in the colon’s inner lining and is the third most common cancer, according to CDC

** Males are more likely to develop this type of cancer than females

** As of last close, EXEL stock up 21.23% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))